...
首页> 外文期刊>Medicinal chemistry >Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as Histone Deacetylase Inhibitors and Antitumor Agents
【24h】

Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as Histone Deacetylase Inhibitors and Antitumor Agents

机译:新型的基于3-取代-2-氧代吲哚啉的N-羟基丙烯酰胺作为组蛋白脱乙酰基酶抑制剂和抗肿瘤剂

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Histone deacetylases (HDAC) are currently a group of validated targets for anticancer drug discovery and development. In our research program to find novel small molecules targeting these enzymes, we designed and synthesized two series of 3-hydroxyimino-2-oxoindoline-and 3-methoxyimino-2-oxoindoline-based N-hydroxypropenamides (3a-g, 6a-g). The results show that these propenamides potently inhibited HDAC2 with IC50 values in sub-micromolar range, approximately 10-fold lower than that of SAHA (also known as suberoylanilohydroxamic acid). Evaluation of cytotoxicity of these compounds in three human cancer cell lines revealed that most of the synthesized compounds were up to 5-fold more cytotoxic than SAHA. Docking studies showed that the compounds bound to HDAC2 at the binding site with higher binding affinities compared to SAHA. Our present results demonstrate that these novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides are potential for further development as anticancer agents.
机译:组蛋白脱乙酰基酶(HDAC)当前是用于抗癌药物发现和开发的一组经过验证的靶标。在我们的研究计划中,发现了针对这些酶的新型小分子,我们设计并合成了两个系列的基于3-羟基亚氨基-2-氧代吲哚啉和基于3-甲氧基亚氨基-2-氧代吲哚啉的N-羟基丙烯酰胺(3a-g,6a-g) 。结果表明,这些丙烯酰胺可有效抑制HDAC2,IC50值在亚微摩尔范围内,比SAHA(也称为次木吡喃基异羟肟酸)低约10倍。这些化合物在三种人类癌细胞系中的细胞毒性评估表明,大多数合成化合物的细胞毒性比SAHA高5倍。对接研究表明,与SAHA相比,该化合物在结合位点以更高的结合亲和力与HDAC2结合。我们目前的研究结果表明,这些新型的基于3取代的2-氧代吲哚啉的N-羟基丙烯酰胺有可能作为抗癌剂进一步发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号